NatuEra granted R&D quotas to cultivate and manufacture psychoactive cannabis

NatuEra granted R&D quotas to cultivate and manufacture psychoactive cannabis

05 November 2020.

During the third quarter of 2020, NatuEra’s wholly-owned subsidiary in Colombia was awarded a total of four R&D quotas by the Colombian government to cultivate cannabis and manufacture cannabis-derived products at its fully-licensed state-of-the-art, vertically-integrated production facilities, strategically located 25 miles outside of Bogota. 

The permits issued by the Ministry of Health and Social Protection and the Ministry of Justice and Law include one cultivation quota to conduct field trials and characterize psychoactive cannabis cultivars, one cultivation quota to conduct R&D related to the manufacture of psychoactive cannabis derivatives, and two R&D manufacturing quotas to analyze and characterize cannabis-derived THC bulk products.

“NatuEra is fully-licensed to cultivate and manufacture psychoactive cannabis products in Colombia and we’re delighted to have been granted these R&D quotas from the Colombian government, which will allow us to evaluate and register proprietary cannabis cultivars, as well as to compile valuable data for the development of THC extracts and bulk products. Once these R&D projects are completed, we expect that we will be able to comply with all applicable requirements to obtain commercial quotas in 2021 to cultivate, manufacture, and export cannabis and cannabis-derived THC bulk products”, explained Nicolas Nannetti, CEO of NatuEra. 

As a producer of essential products with a comprehensive biosecurity protocol compliant with applicable regulations, NatuEra has remained operational throughout the Covid-19 pandemic.

For further information, please see Cronos Group’s 2020 Third Quarter Results: https://ir.thecronosgroup.com/news-releases/news-release-details/cronos-group-reports-2020-third-quarter-results